Essential hypertension, progressive renal disease, and uric acid: A pathogenetic link?

Journal of the American Society of Nephrology

Volumn 16, Issue 7, 2005, Pages 1909-1919

  Johnson, Richard J ^a   Segal, Mark S ^a   Srinivas, Titte ^a   Ejaz, Ahsan ^a   Mu, Wei ^a   Roncal, Carlos ^a   Sánchez Lozada, Laura G ^b   Gersch, Michael ^a   Rodriguez Iturbe, Bernardo ^c   Kang, Duk Hee ^d   Acosta, Jaime Herrera ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^c HOSPITAL UNIVERSITARIO DE MARACAIBO   (Venezuela)

^d Ewha Womans University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ALLOPURINOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GROWTH FACTOR RECEPTOR; LOSARTAN; URIC ACID;

AFRICAN AMERICAN; AGING; ARTERIOSCLEROSIS; BORDERLINE HYPERTENSION; CARDIOVASCULAR DISEASE; CELL COUNT; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG INHIBITION; ESSENTIAL HYPERTENSION; HEART FAILURE; HUMAN; HYPERURICEMIA; KIDNEY DISEASE; KIDNEY FAILURE; LEAD POISONING; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SODIUM RETENTION; STROKE; CHRONIC KIDNEY FAILURE; DISEASE COURSE; HYPERTENSION; METABOLISM; PATHOPHYSIOLOGY;

DISEASE PROGRESSION; HUMANS; HYPERTENSION; HYPERURICEMIA; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; URIC ACID;

EID: 27744608003     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005010063     Document Type: Review

References (171)

1. Morsell JA: The problem of hypertension: A critical review of the literature dealing with its extent. In: A Symposium on Essential Hypertension; An Epidemiologic Approach to the Elucidation of its Natural History in Man. Boston, Wright & Potter Print Co, 1951, pp 26-49
2. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P: The Burden of adult hypertension in the United States 1999 to 2000. A rising tide. Hypertension 44: 398-404, 2004
3. Robinson SC, Brucer M: Range of normal blood pressure. A statistical and clinical study of 11,383 persons. Arch Int Med 64: 409-444, 1939
4. Johnson RJ, Srinivas T, Cade JR, Rideout BA, Oliver WJ: Uric acid, evolution and primitive cultures. Semin Nephrol, 25: 3-8, 2005
5. United States Renal Data System 2003 Annual Data Report: Atlas of end-stage renal disease in the United States. Am J Kid Dis 42[Suppl 5]: S1-S224, 2003
6. Beevers DG, Lip GY: Does nonmalignant essential hypertension cause renal damage? A clinician's view. J Hum Hypertens; 10: 695-699, 1996
7. Rostand SG: Is renal failure caused by primary hypertension? Why does the controversy continue? Nephrol Dial Transpl 13: 3007-3010, 1998
8. Moyer JH, Heider C, Pevey K, Ford RV: The effect of treatment on the vascular deterioration associated with hypertension, with particular emphasis on renal function. Am J Med 24: 177-192, 1958
9. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J: End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 277:1293-1298, 1997
10. Perneger TV, Klag MJ, Feldman HI, Whelton PK: Projections of hypertension-related renal disease in middle-aged residents of the United States. JAMA 269: 1272-1277, 1993
11. Perneger TV, Nieto J, Whelton PK, Klag MJ, Comstock GW, Szklo M: A prospective study of blood pressure and serum creatinine. Results from the "Clue" study and the ARIC study. JAMA 269: 488-493, 1993
12. Haroun MK, Jaar BG, Huffman SC, Comstock GW, Klag MJ, Coresh J: Risk factors for chronic kidney disease: A prospective study of 25,534 men and women in Washington County, Maryland. J Am Soc Nephrol 14: 2394-2941, 2003
13. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end stage renal disease in men. N Engl J Med 334: 13-18, 1996
14. Lindeman RD, Tobin JD, Shock NW: Hypertension and the kidney. Nephron 47[Suppl 1]: 62-67, 1989
15. Zuchelli P: Zuccala. Progression of renal failure and hypertensive nephrosclerosis. Kidney Int 68: S55-S59, 1998
16. Freedman BI, Iskandar SS, Appel RG: The link between hypertension and nephrosclerosis. Am J Kid Dis 25: 207-221, 1995
17. Rosansky SJ, Hoover DR, King L, Gibson J: The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. Arch Intern Med 150: 2073-2076, 1990
18. Hsu CY: Does nonmalignant hypertension cause renal insufficiency? An evidence based perspective. Curr Opin Nephrol Hypertens 11: 267-272, 2002
19. Madhaven S, Stockwell D, Cohen H, Alderman MH: Renal function during antihypertensive treatment. Lancet 345: 749-751, 1995
20. Rostand SG, Brown G, Kirk K, Rutsky EA, Dustan HP: Renal insufficiency in treated essential hypertension. N Engl J Med 320: 684-688, 1989
21. Brazy PC, Fitzwilliam JF: Progressive renal disease: Role of race and antihypertensive medications. Kidney Int 37:1113-1119, 1990
22. DeLeeuw PW: Renal function in the elderly: Results from the European Working Party on High Blood Pressure in the Elderly Trial. Am J Med 90[Suppl 3A]: 45S-49S, 1991
23. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD; for the MRFIT Research Group: Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. JAMA 268: 3085-3091, 1992
24. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S; African American Study of Kidney Disease and Hypertension (AASK) Study Group: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 285: 2719-2728, 2001
25. Kanellis J, Nakagawa T, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B, Johnson RJ: A single pathway for the development of essential hypertension. Cardiol Rev 11: 180-196, 2003
26. Moritz AR, Oldt MR: Arteriolar sclerosis in hypertensive and nonhypertensive individuals. Am J Pathol 13: 679-728, 1937
27. Kimmelsteil P, Wilson C: Benign and malignant hypertension and nephrosclerosis. A clinical and pathological study. Am J Pathol 12: 45-81, 1936
28. Sommers SC, Relman AC, Smithwick RH: Histologic studies of kidney biopsy specimens from patients with hypertension. Am J Pathol 34: 685-715, 1958
29. Sommers SC, Melamed J: Renal pathology of essential hypertension. Am J Hypertens 3: 583-587, 1990
30. Saltz M, Sommers SC, Smithwick RH: Clinicopathologic correlations of renal biopsies from essential hypertension patients. Circulation 16: 207-212, 1957
31. Jones DB: Arterial and glomerular lesions associated with severe hypertension. Lab Invest 31: 303-313, 1974
32. Gómez DM: Evaluation of renal resistances, with special reference to changes in essential hypertension 1. J Clin Invest 30: 1143-1155, 1951
33. Goldring W, Chasis H, Ranges HA, Smith HW: Effective renal blood flow and functional excretory mass in essential hypertension. J Clin Invest 17:505, 1938
34. de Leeuw PW, Birkenhäger: The renal circulation in essential hypertension. J Hypertens 1:321-331, 1983
35. Britton KE: Essential hypertension: A disorder of cortical nephron control? Lancet 2: 900-902, 1981
36. Bohle A, Wehrmann M, Greschniok A, Junghaus R: Renal morphology in essential hypertension: Analysis of 1177 unselected cases. Kidney Int 54[Suppl 67]: S205-S206, 1998
37. Bohle A, Ratschek M: The compensated and the decompensated form of benign nephrosclerosis. Path Res Pract 174: 357-367, 1982
38. Freedman BI, Iskandar SS, Buckalew VM, Burkart JM, Appel RG: Renal biopsy findings in presumed hypertensive nephrosclerosis. Am J Nephrol 14: 90-94, 1994
39. Janeway TC: A clinical study of hypertensive cardiovascular disease. Arch Int Med 12: 755-798, 1913
40. Rasmussen H, Boe J: The prognosis of essential hypertension, with remarks respecting the indications for operative treatment. Acta Med Scand 120: 12-31, 1945
41. Perera GA: Hypertensive vascular disease: Description and natural history. J Chron Dis 1: 34-42, 1955
42. Talbott JH, Castleman B, Smithwick RH, Melville RS, Pecora LJ: Renal biopsy studies correlated with renal clearance observations in hypertensive patients treated by radical sympathectomy. J Clin Invest 22: 387-394, 1943
43. Keith NM, Wagener HP, Barker NW: Some different types of essential hypertension: Their course and prognosis. Am J Med Sci 197: 332-343, 1939
44. Palmer RS, Loofbourow D, Doering CR: Prognosis in essential hypertension. Eight-year followup study of 430 patients on conventional medical treatment. N Engl J Med 239: 990-994, 1948
45. Smithwick RH: Hypertensive cardiovascular disease. Effect of thoracolumbar splanchniectomy on mortality and survival rats. JAMA 147: 1611-1615, 1951
46. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang D-H, Gordon KL, Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38: 1101-1106, 2001
47. Sánchez-Lozada LG, Tapia E, Avila-Casado C, Soto V, Franco M, Santamaria J, Nakagawa T, Rodríguez-Iturbe B, Johnson RJ, Herrera-Acosta J: Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 283: F1105-F1110, 2002
48. Sánchez-Lozada LG, Tapia E, Santamaria J, Avila-Casado C, Soto V, Nepomuceno T, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J: Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 67: 237-247, 2005
49. Lombardi D, Gordon KL, Polinsky P, Suga S, Schwartz SM, Johnson RJ: Salt-sensitive hypertension develops after short-term exposure to angiotensin II. Hypertension 33: 1013-1019, 1999
50. Franco M, Tapia E, Santamaria J, Zafra I, García-Torres R, Gordon KL, Pons H, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J: Renal cortical vasoconstriction contributes to development of salt-sensitive hypertension after angiotensin II exposure. J Am Soc Nephrol 12: 2263-2271, 2001
51. Johnson RJ, Gordon K, Suga S, Griffin K, Bidani A: Renal injury and salt-sensitive hypertension after exposure to catecholamines. Hypertension 34: 151-159, 1999
52. Quiroz Y, Pons H, Gordon KL, Rincón J, Chávez M, Parra G, Herrera-Acosta J, Gomez-Garre D, Largo R, Egido J, Johnson RJ, Rodriguez-Iturbe B: Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol 281: F38-F47, 2001
53. Andoh TF, Johnson RJ, Lam T, Bennett WM: Subclinical renal injury induced by transient cyclosporine exposure is associated with salt-sensitive hypertension. Am J Transpl 1: 222-227, 2001
54. Mazzali M, Jefferson JA, Ni Z, Vaziri ND, Johnson RJ: Microvascular and tubulointerstitial injury associated with chronic hypoxia-induced hypertension. Kidney Intl 63: 2088-2093, 2003
55. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodríguez-Iturbe B: Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 346:913-923, 2002
56. Ericson AC, Sjöquist M, Ulfendahl HR: Heterogeneity in regulation of glomerular function. Acta Physiol Sound 114: 203-209, 1982
57. Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ: Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 286: F606-F616, 2004
58. Guyton AC, Coleman TG, Cowley AV Jr, Scheel KW, Manning RD Jr, Norman RA Jr: Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med. 52:584-594, 1972
59. Sealey JE, Blumenfeld JD, Bell GM, Pecker MS, Sommers SC, Laragh JH: On the renal basis for essential hypertension: Nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. J Hypertens 6: 763-777, 1988
60. Mazzali M, Kanellis J, Ban L, Feng L, Xia Y-Y, Chen Q, Kang D-H, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ: Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282: F991-F997, 2002
61. Suga S, Phillips MI, Ray PE, Raleigh JA, Vio CP, Kim Y-G, Mazzali M, Gordon KL, Hughes J, Johnson RJ: Hypokalemia induces renal injury and alterations in vasoactive mediators that favor salt sensitivity. Am J Physiol Renal Physiol 281: F620-F629, 2001
62. Casellas D, Benahmed S, Artuso A, Jover B: Candesartan and progression of preglomerular lesions in NG-nitro-L-arginine methyl ester hypertensive rats. J Am Soc Nephrol 10: S230-S233, 1999
63. Pichler R, Franceschini N, Young BA, Hugo C, Andoh TF, Burdmann EA, Shankland S, Alpers CE, Bennett WM, Couser WG, Johnson RJ: Pathogenesis of cyclosporine nephropathy: Roles of angiotensin II and osteopontin. J Am Soc Nephrol 6: 1186-1196, 1995
64. Welch WJ, Blau J, Xie H, Chabrashvili T, Wilcox CS: Angiotensin-induced defects in renal oxygenation: Role of oxidative stress. Am J Physiol Heart Circ Physiol 288: H22-H28, 2005
65. Cai H, Griendling KK, Harrison DG: The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 24: 471-478, 2003
66. Arendhorst WJ, Beierwalters WH: Renal and nephron hemodynamics in spontaneously hypertensive rats. Am J Physiol 236: F246-F251, 1979
67. Reams GP, Bauer JH: Acute and chronic effects of angiotensin converting enzyme inhibitors on the essential hypertensive kidney. Cardiovasc Drugs Ther 4: 207-219, 1990
68. Tapia E, Franco M, Sanchez-Lozada LG, Soto V, Avila-Casado C, Santamaria J, Quiroz Y, Rodriguez-Iturbe B, Herrera-Acosta J: Mycophenolate mofetil prevents arteriolopathy and renal injury in subtotal ablation despite persistent hypertension. Kidney Int 63: 994-1002, 2003
69. Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S, Sanchez-Lozada LG, Rodriguez-Iturbe B, Herrera-Acosta J, Johnson RJ: Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 23: 2-7, 2003
70. Weinberger M, Fineberg N: Sodium and volume sensitivity of blood pressure: Age and pressure change over time. Hypertension 18: 67-71, 1991
71. Ljungman S, Aurell M, Hartford M, Wikstrand J, Wilhelmsen L, Berglund G: Blood pressure and renal function. Acta Med Scand 208: 17-25, 1980
72. Willassen Y, Ofstad J: Renal sodium excretion and the peritubular capillary physical factors in essential hypertension. Hypertension 2: 771-779, 1980
73. Hollenberg NK, Borucki LJ, Adams DF: The renal vasculature in early essential hypertension: Evidence for a pathogenetic role. Medicine 57: 167-178, 1978
74. Lindeman RD, Tobin JD, Shock NW: Association between blood pressure and the rate of decline in renal function with age. Kidney Int 26: 861-868, 1984
75. Bigazzi R, Bianchi S, Baldari D, Sherri G, Baldari G, Campese VM: Microalbuminuria in salt-sensitive patients. A marker for renal and cardiovascular risk factors. Hypertension 23: 195-199, 1994
76. Cerasola G, Cottone S, Mule G, Nardi E, Mangano MT, Andronico G, Contorno A, Li Vecchi M, Galione P, Renda F, Piazza G, Volpe V, Lisi A, Ferrara L, Panepinto N, Riccobene R: Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. J Hypertens 14: 915-920, 1996
77. Bigazzi R, Blanch S, Baldari D, Campese VM: Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 16: 1325-1333, 1998
78. Pedrinelli R: Microalbuminuria in hypertension. Nephron 73: 499-505, 1996
79. Reubi FC, Weidman P, Hodler J, Cottier PT: Changes in renal function in essential hypertension. Am J Med 64: 556-562, 1978
80. Moyer JH, Heider C, Pevey K, Ford RV: The vascular status of a heterogeneous group of patients with hypertension, with particular emphasis on renal function. Am J Med 24: 164-176, 1958
81. Bidani AK, Griffin KA: Pathophysiology of hypertensive renal damage. Implications for therapy. Hypertension 44: 595-601, 2004
82. Luke RG: Hypertensive nephrosclerosis: Pathogenesis and prevalence. Nephrol Dial Transpl 14: 2271-2278, 1999
83. Bauer JH: Modern antihypertensive treatment and the progression of renal disease. J Hypertens 16[Suppl 5]: S17-S24, 1998
84. Navar LG: Renal autoregulation: Perspectives from whole kidney and single nephron studies. Am J Physiol 234: F357-F370, 1978
85. Eng E, Verdant M, Floege J, Fingerle J, Alpers CE, Menard J, Clozel J-P, Johnson RJ: Renal proliferative and phenotypic changes in rats with two-kidney, one-clip Goldblatt hypertension. Am J Hypertension 7: 177-185, 1994
86. Wilson C, Byrom FB: The vicious circle in chronic Bright's disease: Experimental evidence. Q J Med 10:65-96, 1940
87. Griffin KA, Picken MM, Bidani AK: Blood pressure lability and glomerulosclerosis after normotensive 5/6 renal mass reduction in the rat. Kidney Int 65: 209-218, 2004
88. Van Dokkum RP, Alonso-Galicia M, Provoost AP, Jacob HJ, Roman RJ: Impaired autoregulation of renal blood flow in the fawn-hooded rat. Am J Physiol 276: R189-R196, 1999
89. Sarkis A, Lopez B, Roman RJ: Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension. Curr Opin Nephrol Hypertens 13: 205-214, 2004
90. Hoagland KM, Flasch AK, Roman RJ: Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats. Hypertension 42: 669-673, 2003
91. Johnson RJ, Kang D-H, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41: 1183-1190, 2003
92. Perry HM, Miller JP, Fornoff JR, Baty JD, Sambhi MP, Rutan G, Moskowitz DW Carmody SE: Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 25: 587-594, 1995
93. Ventura SJ, Anderson RN, Martin JA, Smith BL: Births and deaths: Preliminary data for 1997. Natl Vital Stat Rep 47: 1-41, 1998
94. Hochberg MC, Thomas J, Thomas DJ, Mead L, Levine DM, Klag MJ: Racial differences in the incidence of gout. Arth Rheum 38: 628-632, 1995
95. Greene T: personal communication, February 2004.
96. Dustan H: Growth factors and racial differences in severity of hypertension and renal diseases. Lancet 339: 1339-1340, 1992
97. Suthanthiran M, Khann A, Cukran D, Adhikarla R, Sharma VK, Singh T, August P: Transforming growth factor-betal hyperexpression in African Americans with end-stage renal disease. Kidney Int 53: 639-644, 1998
98. Tobian L: Hypothesis: Low dietary K may lead to renal failure in blacks with hypertension and intimai thickening. Am J Med Sci 295: 384-388, 1988
99. Kahn DF, Duffy SJ, Tomasian D, Holbrook M, Rescorl L, Russell J, Gokce N, Loscalzo J, Vita JA: Effects of black race on forearm resistance vessel function. Hypertension 40:195-201, 2002
100. Dimsdale JE, Graham RM, Ziegler MG, Zusman RM, Berry CC: Age, race, diagnosis and sodium effects on the presser response to infused norepinephrine. Hypertension 10: 564-569, 1987
101. Knox SS, Hausdorff J, Markovitz JH: Reactivity as a predictor of subsequent blood pressure. Hypertension 40: 914-919, 2002
102. Campese VM, Parise M, Karubian F, Bigazzi R: Abnormal renal hemodynamics in black salt-sensitive patients with hypertension. Hypertension 18: 805-812, 1991
103. Fogo A, Breyer JA, Smith MC, Cleveland WH, Lawrence Agodoa, Kirk KA, Glassock R; AASK Pilot Study Investigators: Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: A report from the African American Study of Kidney Disease Trial. Kidney Int 51: 244-252, 1997
104. Marcantoni C, Ma L-J, Federspiel C, Fogo AB: Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int 62: 172-180, 2002
105. Tracy RE, Bhandaru SY, Oalmann MC, Guzman JA, Newman WP: Blood pressure and nephrosclerosis in black and white men and women aged 25 to 54. Modern Pathol 4: 602-609, 1991
106. Weinberger MH: Hypertension in African Americans: The role of sodium chloride and extracellular fluid volume. Semin Nephrol 16: 110-116, 1996
107. El-Gharbawy AH, Kotchen JM, Grim CE, Kaldunski M, Hoffmann RG, Pausova Z, Gaudet D, Gossard F, Hamet P, Kotchen TA: Predictors of target organ damage in hypertensive blacks and whites. Hypertension 38: 761-766, 2001
108. Talbott JH, Terplan KL: The kidney in gout. Medicine 39: 405-466, 1960
109. Coombs FS, Pecora LJ, Thorogood E, Consolazio WV, Talbott JH: Renal function in patients with gout. J Clin Invest 19: 525-535, 1940
110. Brochner-Mortensen K: 100 gouty patients. Acta Medica Scand 106: 81-107, 1941
111. Huchard H: [Allgemeine betrachtungen über die Arteriosklerose]. Klin Med Berlin 5: 1318-1321, 1909
112. Greenbaum D, Ross JH, Steinberg VL: Renal biopsy in gout. Lancet 1: 1502-1504, 1961
113. Linnane JW, Burry AF, Emmerson BT: Urate deposits in the renal medulla. Prevalence and association. Nephron 29: 216-222, 1981
114. Yu TF, Berger L, Dorph DJ, Smith H: Renal function in gout. V. Factors influencing the renal hemodynamics. Am J Med 67: 766-771, 1979
115. Fessel WJ: Renal outcomes of gout and hyperuricemiad. Am J Med 67: 74-82, 1979
116. Beck L: Requiem for gouty nephropathy. Kidney Int. 30: 280-287, 1986
117. Johnson RJ, Kivlighn SD, Kim Y-G, Suga S, Fogo A: Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 33: 225-234, 1999
118. Syrjanen J, Mustonen J, Pasternak A: Hypertriglyceridemia and hyperuricemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transpl 15: 34-42, 2000
119. Ohno I, Hosoya T, Gomi H, Ichida K, Okabe H, Hikita M: Serum uric acid and renal prognosis in IgA nephropathy. Nephron 87: 333-339, 2001
120. Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S: Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 24: 691-697, 2001
121. Tomita M, Mizuno S, Yamanaka H, Hosoda Y, Sakuma K, Matuoka M, Yamaguchi M, Yosida H, Morisawa H, Murayama T: Does hyperuricemia effect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 10: 403-409, 2000
122. Watanabe S, Kang D-H, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, Johnson RJ: Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40: 355-360, 2002
123. Mahomed FA: The etiology of Bright's disease and the prealbuminuric stage. Med Chir Trans 197-228, 1874
124. Bener A, Obineche E, Gillett M, Pasha MAH, Bishawi B: Association between blood levels of lead, blood pressure, and risk of diabetes and heart disease in workers. Int Arch Occup Environ Health 74: 375-378, 2001
125. Shadick NA, Kim R, Weiss S, Liang MH, Sparrow D, Hu H: Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: The Normative Aging Study. J Rheumatol 27: 1708-1712, 2000
126. Sánchez-Fructuoso AI, Torralbo A, Arroyo M, Luque M, Ruilope LM, Santos JL, Cruceyra A, Barrientos A: Occult lead intoxication as a cause of hypertension and renal failure. Nephrol Dial Transpl 11: 1775-1780, 1996
127. Craswell PW, Price J, Boyle PD, Heazlewood VJ, Baddeley H, Lloyd HM, Thomas BJ, Thomas BW: Chronic renal failure with gout: A marker of chronic lead poisoning. Kidney Int 26: 319-323, 1984
128. Lin JL, Tan DT, Ho HH, Yu CC: Environmental lead exposure and urate excretion in the general population. Am J Med 113: 563-568, 2002
129. Bennett WM: Lead nephropathy. Kidney Int 28: 212-220, 1985
130. Muntner P, He J, Vuppururi S, Coresh J, Batuman V: Blood lead and chronic kidney disease in the general United States population: Results from NHANES III. Kidney Int 63: 1044-1050, 2003
131. Emmerson BT: Chronic lead nephropathy: The diagnostic use of calcium EDTA and the association with gout. Australas Ann Med 12: 310-324, 1963
132. Yu CC, Lin JL, Lin-Tan DT: Environmental exposure to lead and progression of chronic renal diseases: A four-year prospective longitudinal study. J Am Soc Nephrol 15: 1016-1022, 2004
133. Inglis JA, Henderson DA, Emmerson BT: The pathology and pathogenesis of chronic lead nephropathy occurring in Queensland. J Pathol 124: 65-76, 1978
134. Emmerson BT: Chronic lead nephropathy. Kidney Int 4: 1-5, 1973
135. Lin JL, Lin-Tan DT, Hus KH, Yu CC: Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med 348: 277-286, 2003
136. Lin JL, Ho HH, Yu CC: Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. Ann Intern Med 130: 7-13, 1999
137. Wilson VK, Thomson ML, Dent CE: Aminoaciduria in lead poisoning: case in childhood. Lancet 2: 66-68, 1953
138. Chisholm JJ, Harrison HC, Eberlein WR, Harrison HE: Aminoaciduria, hypophosphataemia and rickets in lead poisoning. Am J Dis Child 89: 159-168, 1955
139. Hall JE: The kidney, hypertension and obesity. Hypertension 41: 625-633, 2003
140. Kambaham N, Markovitz GS, Velaeri AM, Lin J, D'Agati VD: Obesity-related glomerulopathy: An emerging epidemic. Kidney Int 59: 1498-1509, 2001
141. Dengel DR, Goldberg AP, Mayuga RS, Kairis GM, Weir MR: Insulin resistance, elevated glomerular filtration fraction, and renal injury. Hypertension 28: 127-132, 1996
142. Verani RR: Obesity-associated focal segmental glomerulo-sclerosis: Pathological features of the lesion and relationship with cardiomegaly and hyperlipidemia. Am J Kid Dis 20: 629-634, 1992
143. Schelling JR, Sedor JR: The metabolic syndrome as a risk factor for chronic kidney disease: More than a fat chance? J Am Soc Nephrol 15: 2773-2774, 2004
144. Bagby SP: Obesity-initiated metabolic syndrome and the kidney: A recipe for chronic kidney disease. J Am Soc Nephrol 15: 2775-2791, 2004
145. Facchini F, Chen YD, Hollenbeck CB, GM Reaven: Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266:3008-3011, 1991
146. Rocchini AP, Key J, Bondie D, Chico R, Moorehead C, Katch V, Martin M: The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med 321: 580-585, 1989
147. Coope J, Warrender TS: Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 293: 1145-1151, 1986
148. Coresh J, Wei GL, McQuillan G, Brancati F, Levey A, Jones C, Klag MJ: Prevalence of high blood pressure and elevated serum creatinine level in the United States. Arch Intern Med 161: 1207-1216, 2001
149. Voyaki SM, Staessen JA, Thijs L, Wang JG, Efstratopoulos AD, Birkenhager WH, de Leeuw PW, Leonetti G, Nachev C, Rodicio JL, Tuomilehto J, Fagard R; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. J Hypertens 19:511-519, 2001
150. Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR, Cohen J, Davis BR, Frost P, Smith W, Gonzalez N, Guthrie GP, Oberman A, Rutan G, Probstfield JL, Stamler J: Influence of long-term low-dose diuretic-based antihypertensive therapy on glucose, lipid, uric acid and potassium levels in older men and women with isolated systolic hypertension. The Systolic Hypertension in the Elderly Program. Arch Intern Med 158: 741-751, 1999
151. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM: Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356: 366-372, 2000
152. The ALLHAT Study Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs. diuretic. JAMA 288: 2981-2997, 2002
153. Fletcher A, Amery A, Birkenhager W, Bulpitt C, Clement D, de Leeuw P, Deruyterre ML, de Schaepdryver A, Dollery C, Fagard R: Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. J Hypertens 9: 225-230, 1991
154. De Leeuw PW, Ruilope LM, Palmer CR, Brown MJ, Castaigne A, Mancia G, Rosenthal T, Wagener G: Clinical significance of renal function in hypertensive patients at high risk: Results from the INSIGHT trial. Arch Intern Med 164: 2459-2464, 2004
155. Hawkins RG, Houston MC: Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis. Am J Hypertens 18: 744-749, 2005
156. Ono Y, Ono H, Frohlich ED: Hydrochlorothiazide exacerbates nitric oxide blockade nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats. J Hypertens 14: 823-828, 1996
157. Carlsen JE, Kober L, Torp-Pedersen C, Johansen P: Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 300: 975-978, 1990
158. Korduner Y, Kabin I, Hagbarth G: Low-dose chlorthalidone treatment in previously untreated hypertension. Curr Ther Res Clin Exp 29: 208-215, 1981
159. Wikstrand J, Warnold I, Tuomilehto J, Olsson G, Barber HJ, Eliasson K, Elmfeldt D, Jastrup B, Karatzas NB, Leer J, Marchetta F, Ragnarsson J, Robitaille NM, Valkova L, Wesseling H, Berglund G: Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY study. Hypertension 17: 579-588, 1991
160. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH: Blood pressure, stroke, and coronary heart disease. Part 2. Short term reductions in blood pressure: Overview of randomised drug trials in their epidemiologial context. Lancet 335: 827-838, 1990
161. Medical Research Council Working Party: MRC trial of treatment of mild hypertension: Principal results. BMJ 291: 97-104, 1985
162. Langford HG, Blaufox MD, Borhani NO, Curb JD, Molteni A, Schneider KA, Pressel S: Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med 147: 645-649, 1987
163. Franse LV, Pahor M, Di Bari M, Short RI, Wan JY, Somes GW, Applegate WB: Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program. J Hypertens 18: 1149-1154, 2000
164. Hoieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Chen C, Dahlof B: LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 65: 1041-1049, 2004
165. Dahlof B, Stenkula S, Hansson L: Hypertensive retinal vascular changes: Relationship to left ventricular hypertrophy and arteriolar changes before and after treatment. Blood Press 1: 35-44, 1992
166. Hill GS, Heudes D, Bariéty: Morphometric study of arterioles and glomeruli in the aging kidney suggests focal loss of autoregulation. Kidney Int 63:1027-1036, 2003
167. Ferder LF, Inserra F, Basso N: Advances in our understanding of aging: Role of the renin-angiotensin system. Curr Opin Pharmacol 2: 189-194, 2002
168. Perlstein TS, Gumieniak O, Hopkins PN, Murphey LJ, Brown NJ, Williams GH, Hollenberg NK, Fisher ND: Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int 66: 1465-1470, 2004
169. 1) in vascular endothelial cells and smooth muscle cells [Abstract]. J Am Soc Nephrol 14: 136A, 2003
170. Briney WG, Ogden D, Bartholomew B, Smyth CJ: The influence of allopurinol on renal function in gout. Arthritis Rheum 18: 877-881, 1975
171. Rosenfeld JB: Effect of longterm allopurinol administration on serial GFR in normotensive and hypertensive hyperuricemic subjects. Adv Exp Med Biol 41B: 581-596, 1974